Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06368154
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2024-04-11
Brief Title:
Exosome microRNAs as Potential Biomarkers of Metabolic Bone Disease of Prematurity
Sponsor:
Hunan Childrens Hospital
Organization:
Hunan Childrens Hospital
Study Overview
Official Title:
Prospective Cohort Study of Exosomal microRNAs as Biomarkers for Diagnosis and Therapeutic Efficacy Evaluation of Metabolic Bone Diseases in Premature Infants
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Metabolic bone disease of prematurity MBDP is caused by insufficient content of calcium phosphorus and organic protein matrix in preterm infants or bone metabolism disorder which is one of the complications affecting the quality of life of preterm infants The early symptoms of MBDP are insidious and there is no unified and clear diagnostic method The diagnosis is mostly based on typical clinical manifestations and X-ray findings but at this time bone mineral density has decreased significantly so early detection and diagnosis are difficult Studies have shown that exosomal micrornas have biological characteristics and targeting specificity and can be used as new molecular diagnostic markers for diseases Several studies have reported the use of plasma or serum microRNAs as molecular markers for early prediction of bone diseases In our previous study we extracted plasma exosomes from preterm infants for high-throughput sequencing of microRNAs and identified differentially expressed micrornas related to bone metabolism In this study exosomes were used as carriers and digital PCR was used to verify the specificity and sensitivity of plasma exosomal microRNA as biomarkers of MBDP in a large sample size The above biomarkers were compared and verified before and after treatment in children with MBDP Further revealing plasma exosomal microRNA as a biological indicator for evaluating the efficacy of MBDP may improve the diagnostic level of MBDP improve the outcome and prognosis of very low birth weight preterm infants thereby improving global health and reducing socioeconomic costs
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None